FDA approves a new type of schizophrenia drug
FDA Approves New Kind of Drug for Schizophrenia
FRIDAY, Sept. 27, 2024 (HealthDay News) -- The first new type of medication in decades to help fight against schizophrenia was approved on Thursday by the U.S. Food and Drug Administration.
Bristol Myers wins US FDA approval for new type of schizophrenia drug
The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the first new type of antipsychotic medicine in decades.
FDA approves 1st new drug for schizophrenia in more than 30 years
The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in more than 30 years.
FDA approves a novel drug for schizophrenia, a potential ‘game changer’
The approval comes less than a year Bristol Myers Squibb paid $14 billion to acquire the developer of the drug, Karuna Therapeutics.
Bristol-Myers Stock Jumps on FDA Approval for New Schizophrenia Drug
Shares in Bristol-Myers Squibb (BMY) surged Friday, after the Food and Drug Administration approved the drugmaker's novel treatment for schizophrenia. Bristol-Myers shares stood about 6% higher in recent premarket trading,
This FDA-approved drug promises a new way to treat schizophrenia
Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than antipsychotic treatments
Revolutionary drug for schizophrenia wins US approval
The medication is the first in decades to have a different mode of action than do current drugs, achieving better symptom relief with fewer side effects.
FDA eyes first schizophrenia drug shift in decades
The Food and Drug Administration is slated to decide Thursday whether to approve the first new schizophrenia drug in at least three decades. Why it matters: The complex condition is currently treated with antipsychotics that carry safety risks like metabolic disorders,
The FDA is expected to approve a new type of schizophrenia drug
The Food and Drug Administration is expected to approve KarXT, the first new type of drug for schizophrenia in decades. It appears to be effective, but its main advantage is milder side effects.
The FDA approves a new type of schizophrenia drug
The Food and Drug Administration, as expected, approved KarXT, the first new type of drug for schizophrenia in decades. It appears to be effective, but its main advantage is milder side effects.
FDA eyes 1st schizophrenia drug in decades: 5 things to know
The FDA is set to make a pivotal decision Sept. 26 about KarXT, a novel antipsychotic developed by Karuna Therapeutics. If approved, it would be the first drug with a unique mechanism for treating schizophrenia in decades,
FDA Lifts Clinical Hold On BMF-219
Severity of various FDA product recalls including Class I which can cause death, serious illness
Hundreds of foods are recalled by the FDA every year. Food recalls could fall into different categories, depending on how ...
FDA’s views on AI are evolving
The guidance is based in part on responses the agency received to a 2023 discussion paper on the topic. The paper received ...
FDA Warns Recalled Dog Food Should Be 'Thrown Out or Destroyed'
The pet food was found to be contaminated with bacteria that can cause illness and even death in pets and humans.
FDA issues recall notices for two brands of pet food over salmonella and listeria contamination
Pet owners are advised to throw away the at-risk products safely, so pets and children can't access and ingest them ...
FDA approves new schizophrenia drug
The U.S. Food and Drug Administration has approved a new drug for adults with schizophrenia,  the FDA announced Thursday.
Scones Recall Update As FDA Sets Risk Level
Batches of Blueberry and Marionberry Scones have been recalled because of undeclared soy lecithin and soybean oil on the ...
STAT1d
FDA introduces plan to assess safety of common chemicals added to food
SILVER SPRING, Md. — Food additives rarely face FDA scrutiny once they’re on the market, even those with mounting evidence ...
studyfinds1d
Alzheimer’s drug breakthrough or breakdown? Investigation exposes red flags in FDA approval of donanemab
A startling investigation has revealed a troubling story behind donanemab's approval -- one of questionable data, potential ...